Professor of Paediatrics and Immunology; Consultant in Paediatric Immunology; Head, Rare Diseases Theme; Head, Molecular and Cellular Immunology Section
UCL Great Ormond Street Institute of Child Health
Bobby Gaspar is Professor of Paediatrics and Immunology at UCL Great Ormond Street Institute of Child Health and Honorary Consultant Paediatric Immunologist at Great Ormond Street Hospital for Children NHS Foundation Trust.
Professor Gaspar initially trained in paediatrics and then became interested in primary immunodeficiencies at an early stage in his career and undertook a PhD at the Molecular Immunology Unit at ICH. From there, he has continued his academic and clinical career. He is interested in various aspects of primary immunodeficiency, including understanding the molecular and cellular defects and disease pathogenesis, bone marrow transplantation for severe immunodeficiencies and the development of gene and cell therapy for these conditions. Over the past decade, his team has conducted clinical trials showing that gene therapy can successfully correct the immune defect in specific immunodeficiency conditions.
He leads many UK and European initiatives for newborn screening for severe combined immunodeficiency. He is also Director Designate of the Zayed Centre for Research into Rare Diseases in Children (ZCRRDC), the new academic and clinical facility that will open at Great Ormond Street Hospital for Children in 2018.
Bobby Gaspar is founder and CSO of Orchard Therapeutics, a new company that is developing a lentiviral gene therapy approach for ADA SCID.